title: [Growth hormone deficiency in the adult: only an endocrinologic problem?].
abstract: In the literature published during the last decade an increased risk of death due to cerebrovascular and cardiovascular events in growth hormone deficient adults has been reported. A partial reversibility of the syndrome following recombinant growth hormone treatment has also been described. Both these factors have contributed to the proposal of growth hormone therapy not only for children but also for adults. Following the initial enthusiasm, the scientific community is now evaluating various clinical experiences held over recent years and weighing up the results. Present day medicine has to take the economic impact of prescribed therapeutic regimens into consideration; in other words the ratio between cost and benefits must be calculated. The relatively recent issuance of the license for the treatment of growth hormone deficiency in adults using recombinant growth hormone does not allow us to evaluate a possible reduction in the risk of death due to cerebrovascular and cardiovascular events in treated subjects. A much longer observational period will be required. Besides the partial reversibility of the syndrome as a consequence of treatment, it is necessary to single out the selection criteria for the choice of treatment. These could also be useful as indicators of the efficacy of the same treatment.
authors.affiliation: Clinica Medica III, Dipartimento di Scienze Mediche e Chirurgiche, Università degli Studi di Padova. martinichiara@libero.it
authors.forename: Chiara
authors.initials: C
authors.lastname: Martini
authors.forename: Pietro
authors.initials: P
authors.lastname: Maffei
authors.forename: Eugenio
authors.initials: E
authors.lastname: De Carlo
authors.forename: Roberto
authors.initials: R
authors.lastname: Mioni
authors.forename: Nicola
authors.initials: N
authors.lastname: Sicolo
authors.forename: Cesare
authors.initials: C
authors.lastname: Scandellari
mesh_terms: D000328:Adult; D000375:Aging; D001823:Body Composition; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D019382:Human Growth Hormone / Q000172:deficiency* / Q000627:therapeutic use; D006801:Humans; D007018:Hypopituitarism / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000473:pathology; D018579:Patient Selection; D015995:Prevalence; D011788:Quality of Life; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D018972:Insulin-Like Growth Factor Binding Protein 3; D011994:Recombinant Proteins; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I